id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-325971-volbaipv	Neupane, Karun	Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts	2020-06-26		.txt	text/plain	3017	141	45	Several drugs are being tested in the trials, and the United States Food and Drugs Administration (FDA) has given Emergency Use Authorization (EUA) for remdesivir to treat COVID-19 patients on May 1, 2020 [5] . Therapeutic remdesivir treatment in MERS-CoV inoculated rhesus macaques resulted in the reduction in clinical signs, virus replication, and the absence of lung lesions in 2/6 remdesivirtreated animals along with the reduction in lesion severity in three additional animals. In a randomized controlled clinical trial of 1063 patients conducted by the National Institute of Allergy and Infectious Disease (NIAID), remdesivir has shown the efficacy in the early results against advanced COVID-19 (NCT04280705). In a retrospective observational study involving twenty patients with severe or critical COVID-19, treatment with tocilizumab in addition to lopinavir, methylprednisolone, other symptom relievers, and oxygen therapy, resulted in body temperature of all the patients returning to normal on the first day of receiving tocilizumab and significant relief of clinical symptoms synchronously in the following days.	./cache/cord-325971-volbaipv.txt	./txt/cord-325971-volbaipv.txt